Tag - MRNS

Developments

Marinus gets FDA rare pediatric disease designation for ganaxolone

Marinus Pharmaceuticals (NASDAQ:MRNS) received FDA rare pediatric disease designation for ganaxolone for the treatment of CDKL5 deficiency disorder (CDD). CDD is a rare refractive form of pediatric epilepsy caused by a...

July 31, 2020

Developments

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Marinus Pharmaceuticals (NASDAQ:MRNS) reported positive topline results from its Phase 2 trial of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). Status epilepticus is a prolonged...

September 26, 2019

Markets

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

June 6, 2018

Tag - MRNS

Marinus gets FDA rare pediatric disease designation for ganaxolone

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Ladenburg starts Marinus Pharma at buy; PT $20

General

More